BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 19776757)

  • 1. EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization.
    Goyama S; Nitta E; Yoshino T; Kako S; Watanabe-Okochi N; Shimabe M; Imai Y; Takahashi K; Kurokawa M
    Leukemia; 2010 Jan; 24(1):81-8. PubMed ID: 19776757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel interaction between the proto-oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a.
    Spensberger D; Delwel R
    FEBS Lett; 2008 Aug; 582(18):2761-7. PubMed ID: 18619962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EVI1 recruits the histone methyltransferase SUV39H1 for transcription repression.
    Cattaneo F; Nucifora G
    J Cell Biochem; 2008 Oct; 105(2):344-52. PubMed ID: 18655152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells.
    Shimabe M; Goyama S; Watanabe-Okochi N; Yoshimi A; Ichikawa M; Imai Y; Kurokawa M
    Oncogene; 2009 Dec; 28(49):4364-74. PubMed ID: 19767769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A subset of the histone H3 lysine 9 methyltransferases Suv39h1, G9a, GLP, and SETDB1 participate in a multimeric complex.
    Fritsch L; Robin P; Mathieu JR; Souidi M; Hinaux H; Rougeulle C; Harel-Bellan A; Ameyar-Zazoua M; Ait-Si-Ali S
    Mol Cell; 2010 Jan; 37(1):46-56. PubMed ID: 20129054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RUNX1 associates with histone deacetylases and SUV39H1 to repress transcription.
    Reed-Inderbitzin E; Moreno-Miralles I; Vanden-Eynden SK; Xie J; Lutterbach B; Durst-Goodwin KL; Luce KS; Irvin BJ; Cleary ML; Brandt SJ; Hiebert SW
    Oncogene; 2006 Sep; 25(42):5777-86. PubMed ID: 16652147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells.
    Kondo Y; Shen L; Ahmed S; Boumber Y; Sekido Y; Haddad BR; Issa JP
    PLoS One; 2008 Apr; 3(4):e2037. PubMed ID: 18446223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP.
    Nitta E; Izutsu K; Yamaguchi Y; Imai Y; Ogawa S; Chiba S; Kurokawa M; Hirai H
    Oncogene; 2005 Sep; 24(40):6165-73. PubMed ID: 15897867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SUV39H1 interacts with HTLV-1 Tax and abrogates Tax transactivation of HTLV-1 LTR.
    Kamoi K; Yamamoto K; Misawa A; Miyake A; Ishida T; Tanaka Y; Mochizuki M; Watanabe T
    Retrovirology; 2006 Jan; 3():5. PubMed ID: 16409643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing.
    Gyory I; Wu J; Fejér G; Seto E; Wright KL
    Nat Immunol; 2004 Mar; 5(3):299-308. PubMed ID: 14985713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of EZH2, SUV39H1, G9a and associated molecules in pathogenesis of urethane induced mouse lung tumors: potential targets for cancer control.
    Pandey M; Sahay S; Tiwari P; Upadhyay DS; Sultana S; Gupta KP
    Toxicol Appl Pharmacol; 2014 Oct; 280(2):296-304. PubMed ID: 25168426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency.
    du Chéné I; Basyuk E; Lin YL; Triboulet R; Knezevich A; Chable-Bessia C; Mettling C; Baillat V; Reynes J; Corbeau P; Bertrand E; Marcello A; Emiliani S; Kiernan R; Benkirane M
    EMBO J; 2007 Jan; 26(2):424-35. PubMed ID: 17245432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SUV39H1 interacts with AML1 and abrogates AML1 transactivity. AML1 is methylated in vivo.
    Chakraborty S; Sinha KK; Senyuk V; Nucifora G
    Oncogene; 2003 Aug; 22(34):5229-37. PubMed ID: 12917624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AML1-Evi-1 specifically transforms hematopoietic stem cells through fusion of the entire Evi-1 sequence to AML1.
    Takeshita M; Ichikawa M; Nitta E; Goyama S; Asai T; Ogawa S; Chiba S; Kurokawa M
    Leukemia; 2008 Jun; 22(6):1241-9. PubMed ID: 18337762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional role of G9a-induced histone methylation in small heterodimer partner-mediated transcriptional repression.
    Boulias K; Talianidis I
    Nucleic Acids Res; 2004; 32(20):6096-103. PubMed ID: 15550569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone methyltransferase Suv39h1 represses MyoD-stimulated myogenic differentiation.
    Mal AK
    EMBO J; 2006 Jul; 25(14):3323-34. PubMed ID: 16858404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evi-1 promotes para-aortic splanchnopleural hematopoiesis through up-regulation of GATA-2 and repression of TGF-b signaling.
    Sato T; Goyama S; Nitta E; Takeshita M; Yoshimi M; Nakagawa M; Kawazu M; Ichikawa M; Kurokawa M
    Cancer Sci; 2008 Jul; 99(7):1407-13. PubMed ID: 18452556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation.
    Bartholomew C; Kilbey A; Clark AM; Walker M
    Oncogene; 1997 Feb; 14(5):569-77. PubMed ID: 9053855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of histone lysine methyltransferases SUV39H1 and SETDB1 in gliomagenesis: modulation of cell proliferation, migration, and colony formation.
    Spyropoulou A; Gargalionis A; Dalagiorgou G; Adamopoulos C; Papavassiliou KA; Lea RW; Piperi C; Papavassiliou AG
    Neuromolecular Med; 2014 Mar; 16(1):70-82. PubMed ID: 23943221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3.
    Kurokawa M; Mitani K; Irie K; Matsuyama T; Takahashi T; Chiba S; Yazaki Y; Matsumoto K; Hirai H
    Nature; 1998 Jul; 394(6688):92-6. PubMed ID: 9665135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.